Evidence map›Paper›PMID 41634296›Full record

ArticleScientific reports2026

Bovine serum albumin nanoparticles improve bacteriophage stability and antimicrobial activity against Pseudomonas aeruginosa.

Gustavo Aparecido da Cunha, Giovana Soares Marangoni, Maria Fernanda Romboli Durante, Lais Sanchietta, William Permagnani Gozzi, Matheus Luca Carotta Gabriel, Luiz Cosme Cotta Malaquias, Carine Ervolino de Oliveira, Lara Ambrosio Leal Dutra, Gabriel Magno de Freitas Almeida and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gustavo Aparecido da CunhaVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Giovana Soares MarangoniVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Maria Fernanda Romboli DuranteVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Lais SanchiettaVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
William Permagnani GozziVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Matheus Luca Carotta GabrielVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Luiz Cosme Cotta MalaquiasVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Carine Ervolino de OliveiraInstitute of Biomedical Sciences, Department of Pathology and Parasitology, Federal University of Alfenas, Alfenas, Brazil.
Lara Ambrosio Leal DutraThe Norwegian College of Fishery Science, Faculty of Biosciences, Fisheries and Economics, UiT, The Arctic University of Norway, Tromsø, Norway.
Gabriel Magno de Freitas AlmeidaThe Norwegian College of Fishery Science, Faculty of Biosciences, Fisheries and Economics, UiT, The Arctic University of Norway, Tromsø, Norway.
Luiz Felipe Leomil CoelhoVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil. luiz.coelho@unifal-mg.edu.br.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 408147/2022-9 and 308468/2021-0Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Finance Code 001Fundação de Amparo a Pesquisa do Estado de Minas Gerais PQ-05218-23; APQ-00544-23 and APQ-04845-23
6 · The paper itself

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen characterized by high antimicrobial resistance, which poses significant challenges for treatment. Phage therapy offers a targeted alternative but is limited by the poor stability of phage and phage cocktails under physiological conditions. Here, we report the encapsulation of the anti-P. aeruginosa phage VAC1 in bovine serum albumin (BSA) nanoparticles (NPPha) to increase their stability and antimicrobial performance. NPPha displayed high encapsulation efficiency (> 95%), sustained phage release, and preserved infectivity for up to five days at 37 °C, while showing no cytotoxicity in HepG2 cells. In vitro, compared with free VAC1, NPPha significantly reduced bacterial growth and promoted a > 10⁵-fold increase in phage replication. In a murine model of acute lung infection, NPPha reduced the bacterial burden, increased phage recovery in the lungs, and lowered tissue injury, although survival rates did not improve. These findings highlight the use of albumin-based nanoparticles as a simple, low-cost strategy to stabilize bacteriophages and potentiate their antibacterial activity, with potential applications in phage therapy against multidrug-resistant P. aeruginosa.

Indexed as

NanoparticlesPseudomonas aeruginosaPseudomonas InfectionsPseudomonas PhagesSerum Albumin, BovineAnimalsAnti-Bacterial AgentsCattleHep G2 CellsHumansMicePhage TherapyAnti-Bacterial AgentsSerum Albumin, BovineBSANanoparticlesPhage therapyPseudomonas aeruginosa

Identifiers

PMID41634296
PMCPMC12920805

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.